Stock market analysts have maintained 'buy' rating on Lupin Ltd with an intraday target of Rs 1395.

According to them, interested traders can purchase the stock above Rs 1381 with a strict stop loss of Rs 1365.

If the bourses remain on the positive track, then the stock price will hit a target above Rs 1405.

Shares of the company, on Thursday (Nov 27), closed at Rs 1373.65 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 1365 and a low of Rs 525 on BSE.

Current EPS & P/E ratio stood at 66.64 and 20.52 respectively.

Lupin Ltd, on Nov 05, said that it has allotted 6,79,745 fully paid up equity shares carrying a price of Rs 10 each.

The company's board has allotted 6,77,125 shares issued upon exchange of Zero Coupon FCCBs issued by the company pursuant to the Offering Memorandum dated Jan 2, 2006; and 2,620 shares issued upon exercising the choices allowed to staff under the stock option plans.

With this, the company's issued plus paid up capital has been surged to Rs 88,61,82,670 comprising 8,86,18,267 equity shares worth Rs 10 each.

Lupin, in Oct 2009, announced that it will go in for abroad acquisitions by the next 6 to 9 months. It is discovered that Lupin is talks with some companies in Argentina, Brazil, Gulf and Mexico, as it aims to strengthen its footprint in newer segments.

In 2007, Lupin bought Kyowa in Japan accompanied by a Pharma Dynamics' buy in South Africa during the last year and the newest acquirement of Multicare Pharma in Philippines, earlier this year.

Lupin chairman suggested in 2008 that the company was looking at acquisitions in Middle East and Latin America in order to boost its attendance in this market.